AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00595-07v1
51/9/3457    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guembe, M.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guembe, M.
Right arrow Articles by Bouza, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3457-3458, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00595-07

LETTER TO THE EDITOR

Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes{triangledown}


   LETTER
Top
 LETTER
REFERENCES
 
The use of echinocandins for the treatment of invasive zygomycosis (IZ) is controversial since they show no activity in vitro. Although posaconazole shows promising results, the mortality rates of patients with IZ treated with posaconazole, at 30%, remain unacceptably high. The use of new therapies with alternative agents alone or combined is mandatory.

This is the first study to evaluate the in vitro effect of combining posaconazole (Schering-Plough, Kenilworth, NJ) and caspofungin (MSD, Merck Research Laboratories, Rahway, NJ) against 12 clinical zygomycetes. Zygomycetes were identified by conventional morphological methods (8).

Drug combinations were tested by using a checkerboard modification of the guidelines presented in CLSI document M38-A. The final concentrations of posaconazole and caspofungin were 0.06 to 4 µg/ml and 0.25 to 256 µg/ml, respectively. The adjusted suspensions of sporangiospores had an optical density of 0.15 to 0.17 (68 to 70% transmittance). The MIC for each drug alone and its combinations was defined as the lowest concentration that produced complete visual inhibition of fungal growth (6). Drug interactions were defined as synergistic if the lowest fractional inhibitory concentration index was ≤0.5 (6). Although the caspofungin MICs were all above serum drug levels, the combination proved to be synergistic in all strains (Table 1).


View this table:
[in this window]
[in a new window]

  		TABLE 1. In vitro activities of posaconazole and caspofungin alone and in combination against 12 zygomycete isolates obtained by a checkerboard modification of the CLSI M38-A procedure

 
Caspofungin exhibits minimal activity against zygomycetes when tested in vitro, although this information should be interpreted with caution (10). The mechanisms underlying the lack of activity of echinocandins against zygomycetes are believed to be attributable to differences in their cell wall compositions, as these organisms largely contain 1,3-{alpha}-glucan and glycuronomannoproteins instead of 1,3-ß-D-glucan. However, Rhizopus oryzae expressed the target enzyme for caspofungin (FKS1), and this drug presented limited activity in a murine model of disseminated IZ (3).

Combinations of two drugs have been studied mainly for the treatment of cryptococcal meningitis (5). The combination of caspofungin and posaconazole has been evaluated in other fungi and shows synergy or indifference but never antagonism (1, 7). The combination of two antifungal agents has been shown to be effective against zygomycetes in vitro and in vivo (2). In animal models, the combination of caspofungin and amphotericin B lipid complex was synergistic, improving the survival of mice (9). Few cases of IZ responded partially to the echinocandins, although we have so little clinical experience with caspofungin for the treatment of IZ (4, 11). These data suggest that echinocandins may have a role as a second agent in combinations.

The precise mechanism of synergy found between posaconazole and caspofungin must be shown. A possible explanation may be that the inhibition of the synthesis of ergosterol by posaconazole may be changing the membrane environment and making the enzyme FKS1 more accessible or sensitive to inhibition by caspofungin. The result is that the active agent posaconazole is potentiating the activity of caspofungin. Another possibility is that the effect of caspofungin interfering with the structure of the cell wall may facilitate the penetration of posaconazole into the cell and make this agent more active.

However, the clinical value of these in vitro data is unknown. In vitro-in vivo correlation is needed for this combination.


   ACKNOWLEDGMENTS
 
We thank Thomas O'Boyle for help in the translation of the article.

This study does not present any conflict of interest for its authors.

This study was partially financed by grants from CIBER RES CD06/06/0058 and from Fundación Mutua Madrileña. Jesús Guinea is under contract (no. CM05/00171) by the Fondo de Investigación Sanitaria (FIS).


   FOOTNOTES
 
{triangledown} Published ahead of print on 18 June 2007. Back


   REFERENCES
Top
 LETTER
 REFERENCES
 

  1. Cacciapuoti, A., J. Halpern, C. Mendrick, C. Norris, R. Patel, and D. Loebenberg. 2006. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother. 50:2587-2590.[Abstract/Free Full Text]
  2. Dannaoui, E., J. Afeltra, J. F. G. M. Meis, P. E. Verweij, and The Eurofung Network. 2002. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob. Agents Chemother. 46:2708-2711.[Abstract/Free Full Text]
  3. Ibrahim, A. S., J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards, Jr., and C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-ß-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.[Abstract/Free Full Text]
  4. Jacobs, P., L. Wood, A. Du Toit, and K. Esterhuizen. 2003. Eradication of invasive mucormycosis. Effectiveness of the echinocandin FK463. Hematology 8:119-123.[CrossRef][Medline]
  5. Mukherjee, P. K., D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194.[Abstract/Free Full Text]
  6. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.[Free Full Text]
  7. Oliveira, E. R., A. W. Fothergill, W. R. Kirkpatrick, B. J. Coco, T. F. Patterson, and S. W. Redding. 2005. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob. Agents Chemother. 49:3544-3545.[Abstract/Free Full Text]
  8. Richardson, M. D., and G. S. Shankland. 1999. Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous zygomycoses, p. 1242-1258. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
  9. Spellberg, B., Y. Fu, J. E. Edwards, Jr., and A. S. Ibrahim. 2005. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49:830-832.[Abstract/Free Full Text]
  10. Torres-Narbona, M., J. Guinea, J. Martínez-Alarcón, T. Peláez, and E. Bouza. 2007. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob. Agents Chemother. 51:1126-1129.[Abstract/Free Full Text]
  11. Voitl, P., C. Scheibenpflug, T. Weber, O. Janata, and A. M. Rokitansky. 2002. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 21:632-634.[CrossRef][Medline]
María Guembe
Clinical Microbiology and Infectious Diseases Department
Hospital General Universitario "Gregorio Marañón"
Complutense University of Madrid
28007 Madrid, Spain

Jesús Guinea*
Servicio de Microbiologia Clinica
Hospital General Universitario "Gregorio Marañón"
C/Dr. Esquerdo, 46
28007 Madrid, Spain

Teresa Peláez
Marta Torres-Narbona
Emilio Bouza
Clinical Microbiology and Infectious Diseases Department
Hospital General Universitario "Gregorio Marañón"
Complutense University of Madrid
28007 Madrid, Spain

* Phone: 34914265104, E-mail: jguineaortega{at}yahoo.es

Antimicrobial Agents and Chemotherapy, September 2007, p. 3457-3458, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00595-07




This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00595-07v1
51/9/3457    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guembe, M.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guembe, M.
Right arrow Articles by Bouza, E.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS